TriSalus Life Sciences (TLSI) announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Director, a role he has held since January 2025. In his new capacity, he will lead the Company’s medical strategy and provide clinical leadership across development, evidence generation and broader strategic initiatives.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences price target lowered to $8 from $12.50 at Northland
- TriSalus: Versatile PEDD Platform, Compelling Nelitolimod Data, and Expanding TriNav Revenue Support Buy Rating
- TriSalus Life Sciences Signals Confident Growth Path
- TriSalus Life Sciences price target lowered to $7 from $12 at Canaccord
- TriSalus Life Sciences sees FY26 revenue $60M-$62M, consensus $60.34M